Profound Medical Corp. (PROF) is a Canadian commercial-stage medical device company best known for its TULSA-PRO system, an MRI-guided, incision-free ultrasound platform used to ablate prostate tissue. The stock has rebounded sharply off its 52-week low, and investors are now asking whether it can climb to roughly $11, a level that sits near the center of current Wall Street coverage.
PROF is not yet profitable, so analyst coverage is relatively thin, and only a handful of firms maintain current U.S.-dollar price targets. Reviewing the most recent verifiable targets, three firms stand out: Stifel Nicolaus (analyst Rick Wise) holds a $10 target, Raymond James (Michael Freeman) holds an $11 target, and Lake Street (Ben Haynor) holds a $12 target. The arithmetic mean of these three is $11.00, which serves as the central target throughout this article, with a range of $10 to $12.
The consensus rating across these firms is a unanimous Buy, with no Hold or Sell ratings among current coverage. That unanimity is notable for a small-cap medical device name, though it also reflects the limited number of analysts involved. Earlier coverage was more aggressive — Leede Financial's Douglas Loe carried a $15.25 target in 2025 — but that figure is now considered stale and is excluded. The narrow $10-to-$12 band indicates analysts broadly agree on the company's direction even as they differ modestly on near-term valuation.
The stock traded near $7.44 at the latest close, toward the upper end of a 52-week range of $4.80 to $8.95. Reaching $11 would require an advance of approximately 48% from that level — a substantial move that implies not just continued execution but an expansion of investor confidence in the company's commercial ramp.
PROF remains a commercial-stage business with negative earnings per share (EPS), so the path toward $11 depends less on near-term profit and more on sustained revenue growth from its TULSA-PRO prostate-ablation system and the newer Sonalleve product line. The company recently reported quarterly results that included a wider-than-expected loss, a reminder that revenue scaling and cost discipline remain the central questions for the investment case.
The most meaningful reference points are the 52-week low of $4.80 and the 52-week high of $8.95. The latter is the nearest clear resistance level and, if cleared, would put the stock at a multi-year high on the way toward the $10-to-$12 target zone. On the downside, the 50-day moving average near $6.30 and the 200-day moving average near $6.65 form nearby support, along with the psychological $6 level. The stock's ability to hold above these averages is an important signal for the durability of the recent uptrend.
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms do not always state this explicitly. For PROF, the most important upcoming catalysts are quarterly earnings and revenue results, updates on TULSA-PRO commercial traction and reimbursement, and any changes to analyst estimates or targets. Given the company's reliance on revenue growth, investors should watch gross margins, cash burn, and commentary on new hospital accounts and procedure volumes rather than focusing solely on EPS, which is expected to remain negative in the near term.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. Rather than relying on a single static price target, this approach helps traders spot changing trends, monitor existing positions, and discover new opportunities more efficiently. For investors tracking names like PROF, these signals can offer a timely, data-driven complement to traditional fundamental research.
Whether PROF can reach $11 depends on its ability to sustain revenue growth while narrowing losses, and to hold investor confidence after a strong rally. The central target is an analyst-derived mean of $11, based on a tight $10-to-$12 range, implying a substantial move of roughly 48% from recent levels. The strongest supports are unanimous Buy ratings and an improving technical backdrop, while the principal obstacles are continued losses and the risk that a fast-rising stock consolidates before it can build on its gains. With earnings and commercial milestones still ahead, the target represents a genuine, analyst-grounded objective rather than a near-term certainty, and no outcome is guaranteed.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, PROF has been loosely correlated with OWLT. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if PROF jumps, then OWLT could also see price increases.
| Ticker / NAME | Correlation To PROF | 1D Price Change % | ||
|---|---|---|---|---|
| PROF | 100% | -2.40% | ||
| OWLT - PROF | 36% Loosely correlated | +12.92% | ||
| MTD - PROF | 28% Poorly correlated | +1.42% | ||
| IART - PROF | 28% Poorly correlated | +2.29% | ||
| A - PROF | 26% Poorly correlated | +2.97% | ||
| NEOG - PROF | 25% Poorly correlated | +1.65% | ||
More | ||||
| Ticker / NAME | Correlation To PROF | 1D Price Change % |
|---|---|---|
| PROF | 100% | -2.40% |
| Medical/Nursing Services industry (138 stocks) | -1% Poorly correlated | -0.55% |
| Health Services industry (238 stocks) | -1% Poorly correlated | -1.51% |